Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy.

Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol (2005) 4.35

Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12. J Virol (2001) 1.53

Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology (2007) 1.51

Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. J Virol (2001) 1.42

Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning. J Immunol Methods (2006) 1.19

Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens. J Virol (2008) 1.13

Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J Virol (2011) 1.00

Identification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41. PLoS One (2012) 0.99

A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates. J Virol (2000) 0.99

Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions. J Virol (2007) 0.94

A rapid progressor-specific variant clone of simian immunodeficiency virus replicates efficiently in vivo only in the absence of immune responses. J Virol (2007) 0.89

Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions. J Transl Med (2013) 0.77

Highly efficient neutralization by plasma antibodies from human immunodeficiency virus type-1 infected individuals on antiretroviral drug therapy. J Clin Immunol (2014) 0.76

Sequential antigen panning for selection of broadly cross-reactive HIV-1-neutralizing human monoclonal antibodies. Methods Mol Biol (2009) 0.75

Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. N Engl J Med (1995) 5.69

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. Cell (2001) 4.79

The human immunodeficiency virus type 1 vpr gene arrests infected T cells in the G2 + M phase of the cell cycle. J Virol (1995) 4.42

Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J Virol (1996) 3.84

Quantitative assessment of sustained-release 4-aminopyridine for symptomatic treatment of multiple sclerosis. Neurology (1997) 3.68

High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J Virol (1996) 2.57

Computerised updating of clinical summaries: new opportunities for clinical practice and research? BMJ (1988) 2.49

Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol (1994) 2.45

Genetic analysis of human immunodeficiency virus type 1 integrase and the U3 att site: unusual phenotype of mutants in the zinc finger-like domain. J Virol (1995) 2.22

Does microdamage accumulation affect the mechanical properties of bone? J Biomech (1998) 2.21

Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology (2004) 2.18

Incidence of and risk factors for HIV-associated distal sensory polyneuropathy. Neurology (2002) 2.17

The evolution of diagnosis in early Parkinson disease. Parkinson Study Group. Arch Neurol (2000) 2.08

Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS (1998) 1.99

Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol (2005) 1.99

Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98

Campylobacter laridis colitis in a human immunodeficiency virus-positive patient treated with a quinolone. Clin Infect Dis (1992) 1.97

Freezing of gait in PD: prospective assessment in the DATATOP cohort. Neurology (2001) 1.94

Genealogical evidence for positive selection in the nef gene of HIV-1. Genetics (1999) 1.93

Genetic and biological comparisons of pathogenic and nonpathogenic molecular clones of simian immunodeficiency virus (SIVmac). AIDS Res Hum Retroviruses (1992) 1.92

Factors associated with incident human immunodeficiency virus-dementia. Arch Neurol (2001) 1.91

Structured antiretroviral treatment interruptions in chronically HIV-1-infected subjects. Proc Natl Acad Sci U S A (2001) 1.89

Quantitative functional measures in MS: what is a reliable change? Neurology (2002) 1.81

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. Neurology (2012) 1.77

Neuropathy progression in Charcot-Marie-Tooth disease type 1A. Neurology (2008) 1.70

Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection. J Virol (1993) 1.68

Mexiletine is an effective antimyotonia treatment in myotonic dystrophy type 1. Neurology (2010) 1.67

Expression of Fas (CD95) and Fas ligand on peripheral blood mononuclear cells in critical illness and association with multiorgan dysfunction severity and survival. Crit Care Med (2001) 1.65

A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis (1999) 1.64

Six-Minute Walk Test demonstrates motor fatigue in spinal muscular atrophy. Neurology (2010) 1.63

Is skin biopsy a predictor of transition to symptomatic HIV neuropathy? A longitudinal study. Neurology (2006) 1.57

Inter-rater reliability of a clinical staging of HIV-associated cognitive impairment. Neurology (2003) 1.44

A multiple sclerosis cluster associated with a small, north-central Illinois community. Arch Environ Health (2002) 1.41

ALS defeats gabapentin: reflections on another failed treatment. Neurology (2001) 1.41

Response to immunization with recall and neoantigens after prolonged administration of an HIV-1 protease inhibitor-containing regimen. ACTG 375 team. AIDS Clinical Trials Group. AIDS (2000) 1.38

Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. Neurology (2009) 1.37

Functional and molecular characterization of human monoclonal antibody reactive with the immunodominant region of HIV type 1 glycoprotein 41. AIDS Res Hum Retroviruses (1998) 1.36

QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. Vaccine (2001) 1.35

Facioscapulohumeral dystrophy natural history study: standardization of testing procedures and reliability of measurements. The FSH DY Group. Phys Ther (1994) 1.33

Prevalence of tics in schoolchildren and association with placement in special education. Neurology (2001) 1.32

Apoptosis in AIDS. Apoptosis (2001) 1.31

Natural history of Leishmania (Leishmania) chagasi infection in Northeastern Brazil: long-term follow-up. Clin Infect Dis (2000) 1.28

Survival in Parkinson disease: thirteen-year follow-up of the DATATOP cohort. Neurology (2005) 1.28

Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity. J Virol (1998) 1.28

Markers of immune activation and viral load in HIV-associated sensory neuropathy. Neurology (2005) 1.25

The behavioral spectrum of tic disorders: a community-based study. Neurology (2002) 1.23

Human T-cell leukemia viruses: epidemiology, biology, and pathogenesis. Blood Rev (1997) 1.22

Comparison of cell cycle arrest, transactivation, and apoptosis induced by the simian immunodeficiency virus SIVagm and human immunodeficiency virus type 1 vpr genes. J Virol (2001) 1.21

Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. Parkinson's Study Group. Mov Disord (1998) 1.20

ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis. Cell Death Differ (2005) 1.19

Randomized trials of dichlorphenamide in the periodic paralyses. Working Group on Periodic Paralysis. Ann Neurol (2000) 1.17

The stoichiometry of trimeric SIV glycoprotein interaction with CD4 differs from that of anti-envelope antibody Fab fragments. J Biol Chem (2001) 1.16

Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology (2001) 1.15

Lentivirus vectors using human and simian immunodeficiency virus elements. J Virol (1999) 1.15

Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis (1994) 1.13

The measurement of ambulatory impairment in multiple sclerosis. Neurology (1997) 1.11

Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. J Virol (2000) 1.11

Immunophenotypic characterization of peripheral T lymphocytes in Mycobacterium tuberculosis infection and disease. Clin Exp Immunol (2002) 1.09

[Control of canine visceral leishmaniasis: comparison of results from a rapid elimination program of serum-reactive dogs using an immunoenzyme assay and slower elimination of serum-reactive dogs using filter paper elution indirect immunofluorescence]. Rev Soc Bras Med Trop (1998) 1.08

Quantitative assessment of motor fatigue and strength in MS. Neurology (1999) 1.08

Cytomegalovirus seropositivity is associated with the expansion of CD4+CD28- and CD8+CD28- T cells in rheumatoid arthritis. J Rheumatol (1999) 1.08

Antiparasitic effects of nitric oxide in an in vitro murine model of Chlamydia trachomatis infection and an in vivo murine model of Leishmania major infection. Immunol Ser (1994) 1.08

Toward an HIV type 1 vaccine that generates potent, broadly cross-reactive neutralizing antibodies. AIDS Res Hum Retroviruses (1999) 1.07

Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. FSH-DY Group. Neurology (1994) 1.06

Neuropsychologic status in multiple sclerosis after treatment with glatiramer. Arch Neurol (1999) 1.06

CD26 antigen and HIV fusion? Science (1994) 1.05

Health care costs decline after successful epilepsy surgery. Neurology (2007) 1.04

Tourette's syndrome in a special education population: a pilot study involving a single school district. Neurology (1994) 1.03

Bilineal transmission in Tourette's syndrome families. Neurology (1994) 1.03

Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol Ther (2001) 1.03

Simian immunodeficiency virus (SIV) envelope-specific Fabs with high-level homologous neutralizing activity: recovery from a long-term-nonprogressor SIV-infected macaque. J Virol (1998) 1.02

Upregulation of survivin by HIV-1 Vpr. Apoptosis (2003) 1.02

A randomized controlled trial of telephone peer support's influence on breastfeeding duration in adolescent mothers. Breastfeed Med (2010) 1.01

Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis (1998) 1.01

Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol (1996) 1.00

The presence of a dehydroepiandrosterone-specific receptor binding complex in murine T cells. J Steroid Biochem Mol Biol (1992) 1.00

Th1/Th2-like immunity and resistance to herpes simplex labialis. Antiviral Res (1995) 1.00

Influence of heavy chain constant regions on antigen binding and HIV-1 neutralization by a human monoclonal antibody. J Immunol (1995) 0.99

Roles of p53 and caspases in the induction of cell cycle arrest and apoptosis by HIV-1 vpr. Exp Cell Res (1999) 0.99

Hepatitis B immunization of healthy elderly adults: relationship between naïve CD4+ T cells and primary immune response and evaluation of GM-CSF as an adjuvant. J Clin Immunol (2001) 0.97

Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. Parkinson Study Group. Neurology (1998) 0.97

Mutation of the methylated tRNA(Lys)(3) residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1. J Virol (2001) 0.97

Multigene lentiviral vectors based on differential splicing and translational control. Mol Ther (2001) 0.96

Inhibition of HIV-1 replication using a mutated tRNALys-3 primer. J Biol Chem (1997) 0.95

Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother (1993) 0.94

Predictability by somatic cell counts related to prevalence of intrammary infection within herds. J Dairy Sci (1982) 0.93

Use of a new 'less-sensitive enzyme immunoassay' testing strategy to identify recently infected persons in a Brazilian prison: estimation of incidence and epidemiological tracing. AIDS (1999) 0.93

A phase II study of two HIV type 1 envelope vaccines, comparing their immunogenicity in populations at risk for acquiring HIV type 1 infection. AIDS Vaccine Evaluation Group. AIDS Res Hum Retroviruses (2000) 0.92

Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology (2000) 0.92

A randomized clinical trial of CPI-1189 for HIV-associated cognitive-motor impairment. Neurology (2002) 0.92

Susceptibility to herpes labialis following multiple experimental exposures to ultraviolet radiation. Antiviral Res (1995) 0.92

A prospective natural history study of inclusion body myositis: implications for clinical trials. Neurology (2001) 0.91

Detection of intracellular antigen-specific cytokines in human T cell populations. J Infect Dis (1999) 0.90

Global health research and INCLEN. International Clinical Epidemiology Network. Lancet (1999) 0.90

The global burden of trachomatous visual impairment: I. Assessing prevalence. Int Ophthalmol (1996) 0.89

HTLV type 1 Tax transduction in microglial cells and astrocytes by lentiviral vectors. AIDS Res Hum Retroviruses (2000) 0.89